Novo Nordisk seeks USFDA approval for once weekly CagriSema for weight management
Plainsboro: Novo Nordisk has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4…